Use of Bone-Modifying Agents in Myeloma and Bone Metastases: How Recent Dosing Interval Studies Have Affected Our Practice
2018 ◽
Vol 14
(8)
◽
pp. 457-464
◽
Keyword(s):
The management of bone lesions from advanced solid tumors and multiple myeloma typically includes use of a bone-modifying agent to reduce the risk of skeletal-related events. Recent data demonstrate that when using zoledronic acid to reduce the risk of skeletal-related events in metastatic breast cancer, metastatic prostate cancer, and multiple myeloma, the dosing interval of zoledronic acid may be extended from every 4 weeks to every 12 weeks. The ASCO guidelines on the role of bone-modifying agents in metastatic breast cancer and multiple myeloma address zoledronic acid dosing intervals. Herein, we discuss how new data on dosing of bone-modifying agents influence our clinical practice.
2005 ◽
Vol 28
(1)
◽
pp. 8-16
◽
Keyword(s):
2011 ◽
Vol 29
(15_suppl)
◽
pp. 9025-9025
◽
2007 ◽
Vol 61
(1)
◽
pp. 84-89
◽
Keyword(s):
2007 ◽
Vol 25
(24)
◽
pp. 3787-3787
◽
2019 ◽
Vol 43
(5)
◽
pp. 438-442
◽